A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.

Margaret E Gatti-Mays,Nicholas P Tschernia,Julius Strauss,Ravi A Madan,Fatima H Karzai,Marijo Bilusic,Jason Redman,Houssein Abdul Sater,Charalampos S Floudas,Nicole J Toney,Renee N Donahue,Caroline Jochems,Jennifer L Marté,Deneise Francis,Sheri McMahon,Elizabeth Lamping,Lisa Cordes,Jeffrey Schlom,James L Gulley

The oncologist（2023）

引用 3|浏览35

暂无评分

摘要

Biweekly NHS-IL12 was well tolerated in this small phase I study. Additional studies incorporating NHS-IL12 with other immunomodulating agents are underway. (ClinicalTrials.gov Identifier: NCT01417546).

查看译文

关键词

NHS-IL12,immunocytokine,malignant epithelial tumors,malignant mesenchymal tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要